<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Neuromuscular Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Neuromuscular Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Нервно-мышечные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-8721</issn><issn publication-format="electronic">2413-0443</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">166</article-id><article-id pub-id-type="doi">10.17650/2222-8721-2016-6-3-10-16</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical and immunological features and treatment of myasthenia gravis in the elderly (review)</article-title><trans-title-group xml:lang="ru"><trans-title>Клинико-иммунологические особенности миастении и подходы к ее терапии у лиц пожилого возраста (обзор литературы)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alekseeva</surname><given-names>T. M.</given-names></name><name xml:lang="ru"><surname>Алексеева</surname><given-names>Т. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kosachev</surname><given-names>V. D.</given-names></name><name xml:lang="ru"><surname>Косачев</surname><given-names>В. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khalmurzina</surname><given-names>A. N.</given-names></name><name xml:lang="ru"><surname>Халмурзина</surname><given-names>А. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>eclipse2000@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-04-16" publication-format="electronic"><day>16</day><month>04</month><year>2019</year></pub-date><volume>6</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>10</fpage><lpage>16</lpage><history><date date-type="received" iso-8601-date="2016-10-12"><day>12</day><month>10</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-11-04"><day>04</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Alekseeva T.M., Kosachev V.D., Khalmurzina A.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Алексеева Т.М., Косачев В.Д., Халмурзина А.Н.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Alekseeva T.M., Kosachev V.D., Khalmurzina A.N.</copyright-holder><copyright-holder xml:lang="ru">Алексеева Т.М., Косачев В.Д., Халмурзина А.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://nmb.abvpress.ru/jour/article/view/166">https://nmb.abvpress.ru/jour/article/view/166</self-uri><abstract xml:lang="en"><p>A literature review on the peculiarities of the diagnosis, course and treatment of myasthenia gravis in the elderly has been done. Despite the fact that myasthenia gravis is a disease of the young and middle-aged, in recent years, several authors observe an increased incidence among the elderly. A proper diagnosis in this age group tend to cause difficulties, and concomitant diseases complicate the choice of therapeutic approach which includes: acetylcholinesterase inhibitors, steroids, immunosuppressants, intravenous immunoglobulins and plasmapheresis. Thymectomy in older age groups, except for the presence of thymoma, due to side effects and the lack of a strong evidence base, is not widely held. The question of the effectiveness and optimal therapeutic approach of myasthenia gravis in elderly patients is still not fully resolved.</p></abstract><trans-abstract xml:lang="ru"><p>Проведен обзор отечественной и зарубежной литературы, посвященной особенностям диагностики, течения и лечения миастении у лиц пожилого возраста. Традиционно считается, что миастения чаще встречается у пациентов молодого и среднего возраста,однако в последние годы ряд авторов отмечают рост заболеваемости среди пожилых людей. Диагностика миастении у пожилых, как правило, вызывает трудности, а сопутствующие заболевания осложняют подбор лекарственной терапии, которая включает ингибиторы ацетилхолинэстеразы, глюкокортикостероиды, иммуносупрессоры, внутривенные иммуноглобулины и плазмаферез. Тимэктомия в старших возрастных группах, за исключением случаев наличия тимомы, в силу побочных эффектов и отсутствия убедительной доказательной базы широко не проводится. Вопрос об эффективности различных методов терапии миастении у пациентов пожилого и старческого возраста и оптимальных подходах к лечению этой категории пациентов остается до конца не решенным.</p></trans-abstract><kwd-group xml:lang="en"><kwd>myasthenia gravis</kwd><kwd>elderly</kwd><kwd>acetylcholinesterase inhibitors</kwd><kwd>thymoma</kwd><kwd>Thymectomy</kwd><kwd>intravenous immunoglobulins</kwd><kwd>immunosuppressive therapy</kwd><kwd>myasthenic crisis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>миастения</kwd><kwd>пожилой возраст</kwd><kwd>ингибиторы ацетилхолинэстеразы</kwd><kwd>тимома</kwd><kwd>тимэктомия</kwd><kwd>внутривенные им- муноглобулины</kwd><kwd>иммуносупрессивная терапия</kwd><kwd>миастенический криз</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Санадзе А.Г. Миастения и миастенические синдромы. М.: Литтерра, 2012. 255 с. [Sanadze A.G. Myasthenia and myasthenic syndromes. Moscow: Litterra, 2012. 225 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Санадзе А.Г. Миастения и миастенические синдромы. М.: Литтерра, 2012. 255 с. [Sanadze A.G. Myasthenia and myasthenic syndromes. Moscow: Litterra, 2012. 225 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Лобзин С.В. Миастения: диагностика и лечение. СПб.: СпецЛит, 2015. 160 с. [Lobzin S.V. Myasthenia: diagnosis and treatment. Saint Petersburg: SpetsLit, 2015. 160 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Лобзин С.В. Миастения: диагностика и лечение. СПб.: СпецЛит, 2015. 160 с. [Lobzin S.V. Myasthenia: diagnosis and treatment. Saint Petersburg: SpetsLit, 2015. 160 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Population Ageing and Development 2012. URL: http://www.un.org/en/development/desa/population/publications/ageing/population- ageing-development-2012.shtml (accessed:14.04.2016).</mixed-citation><mixed-citation xml:lang="ru">Population Ageing and Development 2012. URL: http://www.un.org/en/development/desa/population/publications/ageing/population- ageing-development-2012.shtml (accessed:14.04.2016).</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Романова Т.В. Пути оптимизации диагностической и лечебной помощи больным миастенией (анализ опыта работы регионального миастенического центра). Практическая медицина 2012;2(57):153–7. [Romanova T.V. Ways of diagnostic optimization of and curative care in patients with myasthenia (analysis of the regional myastenic center experience). Prakticheskaya meditsina = Practical Medicine 2012;2(57):153–7. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Романова Т.В. Пути оптимизации диагностической и лечебной помощи больным миастенией (анализ опыта работы регионального миастенического центра). Практическая медицина 2012;2(57):153–7. [Romanova T.V. Ways of diagnostic optimization of and curative care in patients with myasthenia (analysis of the regional myastenic center experience). Prakticheskaya meditsina = Practical Medicine 2012;2(57):153–7. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Aragonиs J.M., Bolнbar I., Bonfill X. et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003;60(6):1024–6. DOI: 10.1136/jnnp.74.8.1105. PMID: 12654975.</mixed-citation><mixed-citation xml:lang="ru">Aragonиs J.M., Bolнbar I., Bonfill X. et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003;60(6):1024–6. DOI: 10.1136/jnnp.74.8.1105. PMID: 12654975.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Vincent A., Clover L., Buckley C. et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74(8):1105–8. DOI: 10.1136/jnnp.74.8.1105. PMID: 12876244.</mixed-citation><mixed-citation xml:lang="ru">Vincent A., Clover L., Buckley C. et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74(8):1105–8. DOI: 10.1136/jnnp.74.8.1105. PMID: 12876244.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Murai H., Yamashita N., Watanabe M. et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 2011;305(1–2):97–102. DOI: 10.1016/j.jns.2011.03.004. PMID: 21440910.</mixed-citation><mixed-citation xml:lang="ru">Murai H., Yamashita N., Watanabe M. et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 2011;305(1–2):97–102. DOI: 10.1016/j.jns.2011.03.004. PMID: 21440910.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Somnier F.E. Increasing incidence of lateonset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005;65(6):928–30. PMID: 16186537.</mixed-citation><mixed-citation xml:lang="ru">Somnier F.E. Increasing incidence of lateonset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005;65(6):928–30. PMID: 16186537.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Pakzad Z., Aziz T., Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011;76(17):1526–8. DOI: 10.1212/WNL.0b013e318217e735. PMID: 21519005.</mixed-citation><mixed-citation xml:lang="ru">Pakzad Z., Aziz T., Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011;76(17):1526–8. DOI: 10.1212/WNL.0b013e318217e735. PMID: 21519005.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Гладышев С.С., Гехт Б.М., Коломенская Е.А. Особенности клиники, течения и лечения миастении у лиц пожилого и старческого возраста. Журнал невропатологии и психиатрии им. С.С. Корсакова 1986;(11):23–4. [Gladyshev S.S., Gekht B.M., Kolomenskaya E.A. Clinical and theurapeutic features of myasthenia gravis in elderly and senile age. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neuropathology and Psychiatry 1986;(11):23–4. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Гладышев С.С., Гехт Б.М., Коломенская Е.А. Особенности клиники, течения и лечения миастении у лиц пожилого и старческого возраста. Журнал невропатологии и психиатрии им. С.С. Корсакова 1986;(11):23–4. [Gladyshev S.S., Gekht B.M., Kolomenskaya E.A. Clinical and theurapeutic features of myasthenia gravis in elderly and senile age. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neuropathology and Psychiatry 1986;(11):23–4. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Somnier F.E., Keiding N., Paulson O.B. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 1991;48(7):733–9. PMID: 1859301.</mixed-citation><mixed-citation xml:lang="ru">Somnier F.E., Keiding N., Paulson O.B. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 1991;48(7):733–9. PMID: 1859301.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Лазебник Л.Б., Вёрткин А.Л., Конев Ю.В. и др. Старение: профессиональный врачебный подход. М.: Эксмо, 2014. 320 с. [Lazebnik L.B., Vertkin A.L., Konev Yu.V. et al. Aging: a professional medical approach. Moscow: Eksmo, 2014. 320 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Лазебник Л.Б., Вёрткин А.Л., Конев Ю.В. и др. Старение: профессиональный врачебный подход. М.: Эксмо, 2014. 320 с. [Lazebnik L.B., Vertkin A.L., Konev Yu.V. et al. Aging: a professional medical approach. Moscow: Eksmo, 2014. 320 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Fulop T., Witkowski J.M., Pawelec G. et al. On the immunological theory of aging. Interdiscip Top Gerontol 2014;39:163–76. DOI: 10.1159/000358904. PMID: 24862019.</mixed-citation><mixed-citation xml:lang="ru">Fulop T., Witkowski J.M., Pawelec G. et al. On the immunological theory of aging. Interdiscip Top Gerontol 2014;39:163–76. DOI: 10.1159/000358904. PMID: 24862019.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Ярилин А.А. Иммунология: учебник. М: ГЭОТАР-Медиа, 2010. 752 с. [Yarilin A.A. Immunology: textbook. Moscow: GEOTARMedia, 2010. 752 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Ярилин А.А. Иммунология: учебник. М: ГЭОТАР-Медиа, 2010. 752 с. [Yarilin A.A. Immunology: textbook. Moscow: GEOTARMedia, 2010. 752 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Агафонов Б.В., Котов С.В., Сидорова О.П. Миастения и врожденные миастенические синдромы. М.: Медицинское информационное агентство, 2013. 223 с. [Agafonov B.V., Kotov S.V., Sidorova O.P. Myasthenia and congenital myasthenic syndromes. Moscow: Meditsinskoe informatsionnoe agentstvo, 2013. 223 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Агафонов Б.В., Котов С.В., Сидорова О.П. Миастения и врожденные миастенические синдромы. М.: Медицинское информационное агентство, 2013. 223 с. [Agafonov B.V., Kotov S.V., Sidorova O.P. Myasthenia and congenital myasthenic syndromes. Moscow: Meditsinskoe informatsionnoe agentstvo, 2013. 223 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Weiskopf D., Weinberger B., Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009;22(11):1041–50. DOI: 10.1111/j.1432-2277.2009.00927.x. PMID: 19624493.</mixed-citation><mixed-citation xml:lang="ru">Weiskopf D., Weinberger B., Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009;22(11):1041–50. DOI: 10.1111/j.1432-2277.2009.00927.x. PMID: 19624493.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Ярыгин В.Н., Мелентьев А.С. Руководство по геронтологии и гериатрии. В 4 т. Т. 1. Основы геронтологии. Общая гериатрия. М.: ГЭОТАР-Медиа, 2010. 720 с. [Yarygin V.N., Melent’ev A.S. Guide to gerontology and geriatrics. In 4 vol. Vol. 1. Principles of gerontology. General to geriatrics. Moscow: GEOTAR-Media, 2010. 720 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Ярыгин В.Н., Мелентьев А.С. Руководство по геронтологии и гериатрии. В 4 т. Т. 1. Основы геронтологии. Общая гериатрия. М.: ГЭОТАР-Медиа, 2010. 720 с. [Yarygin V.N., Melent’ev A.S. Guide to gerontology and geriatrics. In 4 vol. Vol. 1. Principles of gerontology. General to geriatrics. Moscow: GEOTAR-Media, 2010. 720 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Chong Y., Ikematsu H., Yamaji K. et al. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(–) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol 2005;17(4):383–90. DOI: 10.1093/intimm/dxh218.PMID: 15724062.</mixed-citation><mixed-citation xml:lang="ru">Chong Y., Ikematsu H., Yamaji K. et al. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(–) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol 2005;17(4):383–90. DOI: 10.1093/intimm/dxh218.PMID: 15724062.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Лайсек Р.П., Барчи Р.Л. Миастения: пер. с англ. М.: Медицина, 1984. 272 с. [Laysek R.P., Barchi R.L. Myasthenia gravis: transl. from Engl. Moscow: Meditsina, 1984. 272 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Лайсек Р.П., Барчи Р.Л. Миастения: пер. с англ. М.: Медицина, 1984. 272 с. [Laysek R.P., Barchi R.L. Myasthenia gravis: transl. from Engl. Moscow: Meditsina, 1984. 272 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Pevzner A., Schoser B., Peters K. et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012;259(3):427–35. DOI: 10.1007/s00415-011-6194-7. PMID: 21814823.</mixed-citation><mixed-citation xml:lang="ru">Pevzner A., Schoser B., Peters K. et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012;259(3):427–35. DOI: 10.1007/s00415-011-6194-7. PMID: 21814823.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Кузин М.И., Гехт Б.М. Миастения. М.: Медицина, 1996. 221 с. [Kuzin M.I., Gekht B.M. Myasthenia. Moscow: Meditsina, 1996. 221 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Кузин М.И., Гехт Б.М. Миастения. М.: Медицина, 1996. 221 с. [Kuzin M.I., Gekht B.M. Myasthenia. Moscow: Meditsina, 1996. 221 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Donaldson D.H., Ansher M., Horan S. et al. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40(5): 786–90. PMID: 2330105.</mixed-citation><mixed-citation xml:lang="ru">Donaldson D.H., Ansher M., Horan S. et al. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40(5): 786–90. PMID: 2330105.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Ishii W., Matsuda M., Hanyuda M. et al. Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma. J Clin Neurosci 2007;14(2):110–5. DOI: 10.1016/j.jocn.2005.11.048. PMID: 17113295.</mixed-citation><mixed-citation xml:lang="ru">Ishii W., Matsuda M., Hanyuda M. et al. Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma. J Clin Neurosci 2007;14(2):110–5. DOI: 10.1016/j.jocn.2005.11.048. PMID: 17113295.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Aarli J.A. Myasthenia gravis in the elderly: Is it different? Ann NY Acad Sci 2008;1132:238–43. DOI: 10.1196/annals.1405.040. PMID: 18567874.</mixed-citation><mixed-citation xml:lang="ru">Aarli J.A. Myasthenia gravis in the elderly: Is it different? Ann NY Acad Sci 2008;1132:238–43. DOI: 10.1196/annals.1405.040. PMID: 18567874.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Suzuki S., Utsugisawa K., Nagane Y. et al. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 2011;230(1–2):148–52. DOI: 10.1016/j.jneuroim.2010.10.023. PMID: 21074862.</mixed-citation><mixed-citation xml:lang="ru">Suzuki S., Utsugisawa K., Nagane Y. et al. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 2011;230(1–2):148–52. DOI: 10.1016/j.jneuroim.2010.10.023. PMID: 21074862.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Slesak G., Melms A., Gerneth F. et al. Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci 1998;841:777–80. DOI: 10.1111/j.1749-6632.1998.tb11017.x. PMID: 9668329.</mixed-citation><mixed-citation xml:lang="ru">Slesak G., Melms A., Gerneth F. et al. Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci 1998;841:777–80. DOI: 10.1111/j.1749-6632.1998.tb11017.x. PMID: 9668329.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Evoli A., Batocchi A.P., Minisci C. et al. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 2000;48(11):1442–8. DOI:10.1111/j.1532-5415.2000.tb02635.x. PMID: 11083321.</mixed-citation><mixed-citation xml:lang="ru">Evoli A., Batocchi A.P., Minisci C. et al. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 2000;48(11):1442–8. DOI:10.1111/j.1532-5415.2000.tb02635.x. PMID: 11083321.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Christensen P.B., Jensen T.S., Tsiropoulos I. et al. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand 1995;91(3):192–5. DOI: 10.1111/j.1600-0404.1995.tb00432.x. PMID: 7793234.</mixed-citation><mixed-citation xml:lang="ru">Christensen P.B., Jensen T.S., Tsiropoulos I. et al. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand 1995;91(3):192–5. DOI: 10.1111/j.1600-0404.1995.tb00432.x. PMID: 7793234.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Косачев В.Д. Оптимизация диагностики, лечения и прогнозирования миастении. Автореф. дис. … д-ра мед. наук. СПб., 2007. 44 с. [Kocachev V.D. Optimization of diagnostics, treatment and prognosis of myasthenia gravis. Thesis … of doctor of medical sciences. Saint Petersburg, 2007. 44 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Косачев В.Д. Оптимизация диагностики, лечения и прогнозирования миастении. Автореф. дис. … д-ра мед. наук. СПб., 2007. 44 с. [Kocachev V.D. Optimization of diagnostics, treatment and prognosis of myasthenia gravis. Thesis … of doctor of medical sciences. Saint Petersburg, 2007. 44 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Санадзе А.Г., Сиднев Д.В., Ланцова В.Б. и др. Клинические, электрофизиологические и иммунологические особенности миастении пожилого возраста и миастении в сочетании с тимомой. Патогенез 2003;(2):62–6. [Sanadze A.G., Sidnev D.V., Lantsova V.B. et al. Clinical, electrophysiological and immunological features in late-onset myasthenic patients and patients with myasthenia, associated with thymoma. Patogenez =Pathogenesis 2003;(2):62–6. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Санадзе А.Г., Сиднев Д.В., Ланцова В.Б. и др. Клинические, электрофизиологические и иммунологические особенности миастении пожилого возраста и миастении в сочетании с тимомой. Патогенез 2003;(2):62–6. [Sanadze A.G., Sidnev D.V., Lantsova V.B. et al. Clinical, electrophysiological and immunological features in late-onset myasthenic patients and patients with myasthenia, associated with thymoma. Patogenez =Pathogenesis 2003;(2):62–6. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Щербакова Н.И., Пирадов М.А., Павлова Е.М. и др. Причины, факторы риска, клинические предикторы развития кризов у больных миастенией. Неврологический журнал 2013;18(2):11–9. [Shcherbakova N.I., Piradov M.A., Pavlova E.M. et al. The causes, risk factors and predictors of myasthenia gravis crisis. Nevrologicheskiy zhurnal = Neurological Journal 2013;18(2):11–9. (In Russ.)]. DOI: http://dx.doi.org/10.18821/1560-9545- 2013-18-2-11-19.</mixed-citation><mixed-citation xml:lang="ru">Щербакова Н.И., Пирадов М.А., Павлова Е.М. и др. Причины, факторы риска, клинические предикторы развития кризов у больных миастенией. Неврологический журнал 2013;18(2):11–9. [Shcherbakova N.I., Piradov M.A., Pavlova E.M. et al. The causes, risk factors and predictors of myasthenia gravis crisis. Nevrologicheskiy zhurnal = Neurological Journal 2013;18(2):11–9. (In Russ.)]. DOI: http://dx.doi.org/10.18821/1560-9545- 2013-18-2-11-19.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Palace J., Newsom-Davis J., Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50(6):1778–83. PMID: 9633727.</mixed-citation><mixed-citation xml:lang="ru">Palace J., Newsom-Davis J., Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50(6):1778–83. PMID: 9633727.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">33. Punga A.R., Sawada M., Stеlberg E.V. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008;37(3):300–7. DOI: 10.1002/mus.20935. PMID: 18069667.</mixed-citation><mixed-citation xml:lang="ru">Punga A.R., Sawada M., Stеlberg E.V. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008;37(3):300–7. DOI: 10.1002/mus.20935. PMID: 18069667.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">34. Nagappa M., Netravathi M., Taly A.B. et al. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci 2014;21(11):1909–14. DOI: 10.1016/j.jocn.2014.03.019. PMID: 25043165.</mixed-citation><mixed-citation xml:lang="ru">Nagappa M., Netravathi M., Taly A.B. et al. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci 2014;21(11):1909–14. DOI: 10.1016/j.jocn.2014.03.019. PMID: 25043165.</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">35. Nakamura S., Kaneko S., Shinde A. et al. Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis. Neuromuscul Disord 2013;23(2): 176–9. DOI: 10.1016/j.nmd.2012.11.003. PMID: 23237872.</mixed-citation><mixed-citation xml:lang="ru">Nakamura S., Kaneko S., Shinde A. et al. Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis. Neuromuscul Disord 2013;23(2): 176–9. DOI: 10.1016/j.nmd.2012.11.003. PMID: 23237872.</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">36. Sanders D.B., McDermott M., Thornton C. et al. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71(6):394–9. DOI: 10.1212/01.wnl.0000312373.67493.7f. PMID: 18434639.</mixed-citation><mixed-citation xml:lang="ru">Sanders D.B., McDermott M., Thornton C. et al. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71(6):394–9. DOI: 10.1212/01.wnl.0000312373.67493.7f. PMID: 18434639.</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">37. Ponseti J.M., Gamez J., Azem J. et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci 2008;1132:254–63. DOI: 10.1196/annals.1405.000. PMID: 18096852.</mixed-citation><mixed-citation xml:lang="ru">Ponseti J.M., Gamez J., Azem J. et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci 2008;1132:254–63. DOI: 10.1196/annals.1405.000. PMID: 18096852.</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">38. Zinman L., Bril V. IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies. Ann NY Acad Sci 2008;1132:264–70. DOI: 10.1196/annals.1405.038. PMID: 18567877.</mixed-citation><mixed-citation xml:lang="ru">Zinman L., Bril V. IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies. Ann NY Acad Sci 2008;1132:264–70. DOI: 10.1196/annals.1405.038. PMID: 18567877.</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">39. Basic-Jukic N., Brunetta B., Kes P. Plasma exchange in elderly patients. Ther Apher Dial 2010;14(2):161–5. DOI: 10.1111/j.1744-9987.2009.00793.x. PMID: 20438537.</mixed-citation><mixed-citation xml:lang="ru">Basic-Jukic N., Brunetta B., Kes P. Plasma exchange in elderly patients. Ther Apher Dial 2010;14(2):161–5. DOI: 10.1111/j.1744-9987.2009.00793.x. PMID: 20438537.</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">40. Алексеева Т.М., Шабашова Н.В. Новые концепции патогенеза и терапии аутоиммунных нервно-мышечных болезней (по материалам XIII Международного конгресса по нервно-мышечным болезням, Ницца, Франция, 5–10 июля 2014 г.). Вестник Санкт-Петербургского университета 2015;11(3):71–82. [Alekseeva T.M., Shabashova N.V. New concepts in pathogenesis and therapy of autoimmune neuromuscular diseases (based on the XIII International Congress on Neuromuscular Diseases, Nice, France, 5–10 July 2014). Vestnik Sankt-Peterburgskogo universiteta = Bulletin of SaintPetersburg University 2015;11(3):71–82. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Алексеева Т.М., Шабашова Н.В. Новые концепции патогенеза и терапии аутоиммунных нервно-мышечных болезней (по материалам XIII Международного конгресса по нервно-мышечным болезням, Ницца, Франция, 5–10 июля 2014 г.). Вестник Санкт-Петербургского университета 2015;11(3):71–82. [Alekseeva T.M., Shabashova N.V. New concepts in pathogenesis and therapy of autoimmune neuromuscular diseases (based on the XIII International Congress on Neuromuscular Diseases, Nice, France, 5–10 July 2014). Vestnik Sankt-Peterburgskogo universiteta = Bulletin of SaintPetersburg University 2015;11(3):71–82. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">41. Щербакова Н.И., Супонева Н.А., Шведков В.В. и др. Российский опыт успешного применения ритуксимаба при рефрактерных формах миастении гравис. Нервно-мышечные болезни 2015;5(3): 50–61. [Shcherbakova N.I., Suponeva N.A., Shvedkov V.V. et al. Positive experience of the usage of rituximab in management of refractory myasthenia gravis in Russia. Nervno-myshechnye bolezni = Neuromuscular Diseases 2015;5(3):50–61. (In Russ.)]. DOI: 10.17650/2222-8721-2015-5-3-50-61.</mixed-citation><mixed-citation xml:lang="ru">Щербакова Н.И., Супонева Н.А., Шведков В.В. и др. Российский опыт успешного применения ритуксимаба при рефрактерных формах миастении гравис. Нервно-мышечные болезни 2015;5(3): 50–61. [Shcherbakova N.I., Suponeva N.A., Shvedkov V.V. et al. Positive experience of the usage of rituximab in management of refractory myasthenia gravis in Russia. Nervno-myshechnye bolezni = Neuromuscular Diseases 2015;5(3):50–61. (In Russ.)]. DOI: 10.17650/2222-8721-2015-5-3-50-61.</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">42. Strober J., Cowan M.J., Horn B.N. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 2009;66(5):659–61. DOI: 10.1001/archneurol.2009.28. PMID: 19433668.</mixed-citation><mixed-citation xml:lang="ru">Strober J., Cowan M.J., Horn B.N. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 2009;66(5):659–61. DOI: 10.1001/archneurol.2009.28. PMID: 19433668.</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">43. Bryant A., Atkins H., Pringle C.E. et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol 2016;73(6):652–8. DOI: 10.1001/jamaneurol.2016.0113. PMID: 27043206.</mixed-citation><mixed-citation xml:lang="ru">Bryant A., Atkins H., Pringle C.E. et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol 2016;73(6):652–8. DOI: 10.1001/jamaneurol.2016.0113. PMID: 27043206.</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">44. Зайратьянц О.В., Ветшев П.С., Ипполитов И.Х. и др. Морфологическая и клинико-иммунологическая характеристика двух типов миастении. Клиническая медицина 1991;69(12):78–83. [Zayrat’yants O.V., Vetshev P.S., Ippolitov I.Kh. et. al. Clinicoimmunological features of generalized myasthenia in patients with hyper plasia and atrophy of the thymus gland. Klinicheskaya meditsina =Clinical Medicine 1991;69(12): 78–83. (In Russ.)]. PMID: 1787688.</mixed-citation><mixed-citation xml:lang="ru">Зайратьянц О.В., Ветшев П.С., Ипполитов И.Х. и др. Морфологическая и клинико-иммунологическая характеристика двух типов миастении. Клиническая медицина 1991;69(12):78–83. [Zayrat’yants O.V., Vetshev P.S., Ippolitov I.Kh. et. al. Clinicoimmunological features of generalized myasthenia in patients with hyper plasia and atrophy of the thymus gland. Klinicheskaya meditsina =Clinical Medicine 1991;69(12): 78–83. (In Russ.)]. PMID: 1787688.</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">45. Uzawa A., Kawaguchi N., Kanai T. et al. Two-year outcome of thymectomy in nonthymomatous late-onset myasthenia gravis. J Neurol 2015;262(4):1019–23. DOI: 10.1007/s00415-015-7673-z. PMID: 25683765.</mixed-citation><mixed-citation xml:lang="ru">Uzawa A., Kawaguchi N., Kanai T. et al. Two-year outcome of thymectomy in nonthymomatous late-onset myasthenia gravis. J Neurol 2015;262(4):1019–23. DOI: 10.1007/s00415-015-7673-z. PMID: 25683765.</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">46. Romi F., Gilhus N.E., Varhaug J.E. et al. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol 2002;9(1):55–61. PMID: 11784377.</mixed-citation><mixed-citation xml:lang="ru">Romi F., Gilhus N.E., Varhaug J.E. et al. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol 2002;9(1):55–61. PMID: 11784377.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
